Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome

Annals of Pharmacotherapy

Volumn 38, Issue 7-8, 2004, Pages 1215-1218

  Payne, Sonja M ^a   Kovacs, Michael J ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Hypereosinophilic syndrome; Imatinib mesylate; Treatment

Indexed keywords

IMATINIB;

ADULT; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERABILITY; HUMAN; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; MALE; PRIORITY JOURNAL; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; HUMANS; HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE COUNT; MALE; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 3042636802     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D505     Document Type: Article

References (13)

1. Bunc M, Remskar Z, Brucan A. The idiopathic hypereosinophilic syndrome. Eur J Emerg Med 2001;8:325-30.
2. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759-79.
3. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome; analysis of fourteen cases with review of literature. Medicine 1975;54:1-10.
4. Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003;54:169-84.
5. Lefebvre C, Bletry O, Degoulet P, Guillerin L, Bentata-Pessayre M, Le Thi Huong D, et al. [Prognostic factors of hypereosinophilic syndrome. Study of 40 cases.] French. Ann Med Interne 1989;140:253-7.
6. Ault P, Cortes J, Koller C, Kaled E, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 2002;26:881-4.
7. Pardanani A, Reeder T, Porrata LF, Chin-Yang L, Tazelaar HD, Baxter EJ, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101:3391-7.
8. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
9. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib. Eur J Cancer 2002;38(suppl 5):S28-36.
10. Capdeville R, Silberman S, Dimitrijevic S. Imatinib: the first 3 years. Eur J Cancer 2002;38(suppl 5):S77-82.
11. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64.
12. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002;359:1577-8.
13. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003;101:4714-6.